Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Renal cell cancer (RCC) is the most common form of cancer of the kidney and accounts for approximately 44,000 cases per year in the United States. Historically, only immunotherapy showed activity in metastatic RCC. The improved survival and quality of life for patients with metastatic RCC over the last several years are direct results of advances made in understanding the development of RCC. Three targeted therapies-sunitinib, sorafenib, and temsirolimus-have been approved for use in the United States recently. Current research is aimed at developing new drugs and combining available drugs to improve upon the responses and survival seen with approved single agents.

Written by:
Kroog GS, Motzer RJ.   Are you the author?

Reference:
Urol Clin North Am. 2008 Nov;35(4):687-701.
doi:10.1016/j.ucl.2008.07.007

PubMed Abstract
PMID:18992622

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!